Wall Street Zen upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO – Free Report) to a hold rating in a research report report published on Saturday morning.
Latigo Biotherapeutics Stock Performance
Latigo Biotherapeutics stock opened at $19.30 on Friday. Latigo Biotherapeutics has a 52 week low of $17.22 and a 52 week high of $22.47.
Insider Activity at Latigo Biotherapeutics
In other news, Director James B. Tananbaum bought 140,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.
About Latigo Biotherapeutics
Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.
Read More
- Five stocks we like better than Latigo Biotherapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
